What is the official website of Cipla Africa ?

The official website of Cipla Africa is https://cipla.africa/.

What is Cipla Africa's cybersecurity risk score?

Cipla Africa has an AI-generated cybersecurity risk score of 758 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Cipla Africa experienced?

According to Rankiteo, Cipla Africa currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Cipla Africa been affected by any supply chain cyber incidents ?

According to Rankiteo, Cipla Africa has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Cipla Africa have SOC 2 Type 1 certification ?

According to Rankiteo, Cipla Africa is not certified under SOC 2 Type 1.

Does Cipla Africa have SOC 2 Type 2 certification ?

According to Rankiteo, Cipla Africa does not hold a SOC 2 Type 2 certification.

Does Cipla Africa comply with GDPR ?

According to Rankiteo, Cipla Africa is not listed as GDPR compliant.

Does Cipla Africa have PCI DSS certification ?

According to Rankiteo, Cipla Africa does not currently maintain PCI DSS compliance.

Does Cipla Africa comply with HIPAA ?

According to Rankiteo, Cipla Africa is not compliant with HIPAA regulations.

Does Cipla Africa have ISO 27001 certification ?

According to Rankiteo,Cipla Africa is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Cipla Africa operate in ?

Cipla Africa operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Cipla Africa have ?

Cipla Africa employs approximately 723 people worldwide.

Does Cipla Africa own any subsidiaries ?

Cipla Africa presently has no subsidiaries across any sectors.

How many LinkedIn followers does Cipla Africa have ?

Cipla Africa's official LinkedIn profile has approximately 70,237 followers.

What is the NAICS classification code for Cipla Africa ?

Cipla Africa is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Cipla Africa have a Crunchbase profile ?

No, Cipla Africa does not have a profile on Crunchbase.

Does Cipla Africa have a LinkedIn profile ?

Yes, Cipla Africa maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/cipla-africa.

How many cybersecurity incidents has Cipla Africa experienced ?

As of August 3, 2026, Rankiteo reports that Cipla Africa has not experienced any cybersecurity incidents.

How many peer or competitor companies does Cipla Africa have ?

Cipla Africa has an estimated 5,720 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Cipla Africa

Boost Score +25 with badge (5 left)

758

/1000

Fair

783

/1000

Fair

Cipla Africa Vendor Cyber Rating & Cyber Score

cipla.africa

Add Your Compliance Badge

Cipla Medpro South Africa (Pty) Limited is the third largest pharmaceutical manufacturer in the country. Through Cipla’s ethos of ‘Caring for Life’, Cipla Medpro produces world-class medicines at affordable prices for the public and private sectors, advancing healthcare for all South Africans. For more information, visit https://cipla.africa/

Cipla Africa A.I CyberSecurity Scoring

Scoring History

Cipla Africa

Cipla Africa CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Cipla Africa Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Cipla Africa

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Cipla Africa in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Cipla Africa in 2026.

Incident Types Cipla Africa vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Cipla Africa in 2026.

Incident History - Cipla Africa (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Cipla Africa Subsidiaries

Cipla Africa

Pharmaceutical Manufacturing

Website: https://cipla.africa/

Company Size: 723

CiplaPharmaceutical Manufacturing

Cipla FoundationNon-profit Organizations

Cipla TherapeuticsPharmaceutical Manufacturing

Cipla FoundationNon-profit Organizations

Cipla ALIVEPharmaceutical Manufacturing

Cipla USAPharmaceutical Manufacturing

Cipla Australia & New ZealandPharmaceutical Manufacturing

Loading…

Cipla Africa Similar Companies

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Loading…

NEWS

Cipla Africa CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

September 21, 2023 07:00 AM

Cipla's US subsidiary InvaGen gets 5 inspectional observations from USFDA

Cipla announced that the United States Food and Drug Administration (USFDA) had conducted an inspection at its wholly-owned subsidiary, InvaGen Pharmaceuticals.

Read Article

September 05, 2023 07:00 AM

Cipla to bolster OTC portfolio with acquisition of Actor Pharma

Cipla Medpro South Africa has signed a binding term sheet to acquire Actor Pharma to bolster over-the-counter (OTC) product portfolio.

Read Article

August 08, 2020 07:00 AM

Cipla Q1 results: Net profit rises 27% to Rs 566 crore; beats Street expectations

Drugmaker Cipla reported a net profit of Rs 566.04 crore for the quarter ended June, an increase of 26.58% on the back of robust sales.

Read Article

February 11, 2020 08:00 AM

Luye Pharma grants certain rights for Seroquel to Cipla Medpro

Luye Pharma Group has granted Cipla Medpro exclusive rights to distribute and market antipsychotic drug Seroquel in South Africa,...

Read Article

April 03, 2017 07:00 AM

Cipla acquires South Africa-based firm for R26m

Pharma major Cipla today said its arm Medpro South Africa (Pty) Limited has signed an agreement to acquire 100 per cent stake in Anmarate...

Read Article

October 18, 2016 07:00 AM

Cipla Biosimilars Manufacturing Facility, Durban, South Africa

India-based pharmaceutical company Cipla has announced plans to build a manufacturing facility in Durban, KwaZulu-Natal, South Africa.

Read Article

July 29, 2008 07:00 AM

Cipla Medpro Pharmaceuticals, South Africa

Cipla Medpro Pharmaceuticals is listed on the Johannesburg Securities Exchange and is one of South Africa's top ten and fastest-growing pharmaceutical groups.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-18577

SUMMARY

An incomplete patch for CVE-2026-18556 allows for authentication bypass and account takeover in N-central Versions through 2026.3.1

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:L/SI:L/SA:L/E:A/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-10848

SUMMARY

The OCPP 1.6 client in subsys/net/lib/ocpp parsed inbound WAMP RPC frames in parse_rpc_msg() (subsys/net/lib/ocpp/ocpp_j.c) using a hand-rolled helper, extract_string_field(), that copied the message's uid and action fields with strncpy(out_buf, token + 1, outlen - 1) and then scanned the result with strchr(out_buf, '"'). Because strncpy does not NUL-terminate the destination when the source is at least outlen - 1 (127) bytes long, the subsequent strchr reads past the 128-byte destination buffer into adjacent stack memory; if a " byte is found beyond the buffer, a one-byte out-of-bounds NUL write also occurs. A related defect in extract_payload() runs strchr/strrchr over the receive buffer, which may not be NUL-terminated when a maximal-length frame fills it. The parsed bytes come directly from the OCPP central-system server over a websocket: the reader thread fills recv_buf via websocket_recv_msg() and calls parse_rpc_msg() on each inbound DATA frame (subsys/net/lib/ocpp/ocpp.c). A malicious or compromised central server, or an on-path attacker (OCPP is commonly deployed over plain ws://), can send an RPC frame whose uid or action field is 127+ bytes with no closing quote, triggering the out-of-bounds access. The primary impact is a remotely triggerable denial of service: the unbounded scan can fault on an unmapped page, and the stray NUL write can corrupt adjacent stack state. The over-read data is not reflected to the peer, so disclosure is limited. The feature is EXPERIMENTAL and must be explicitly enabled (CONFIG_OCPP). The fix replaces the manual parser with the bounds-respecting json_mixed_arr_parse() and copies the extracted uid with an explicitly NUL-terminated buffer, eliminating both over-reads.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 7)

cvss3

Base Score: 7.0

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:L/A:H

Impact Score

4.7

Exploitability

2.2

REFERENCES

CVE-2026-9856

SUMMARY

A vulnerability in huggingface/transformers versions <=5.8.0.dev0 allows an attacker to perform arbitrary file writes via path traversal. The issue resides in the `save_pretrained()` methods of `PreTrainedTokenizerBase` and `ProcessorMixin`, where keys from the `chat_template` dictionary are used directly as filenames without proper validation. An attacker can exploit this by publishing a malicious Hugging Face Hub repository with a crafted `tokenizer_config.json` file. When a victim downloads and saves the tokenizer or processor, the attacker-controlled keys can escape the intended save directory, enabling arbitrary file writes with attacker-controlled content. This vulnerability affects multiple processors inheriting from `ProcessorMixin`, including Idefics, Florence, Gemma, Phi, and Qwen-VL.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.0/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:H/A:L

Impact Score

4.2

Exploitability

2.8

REFERENCES

CVE-2026-65321

SUMMARY

PyAthena prior to 3.35.4 contains a sql injection vulnerability that allows unauthenticated attackers to inject arbitrary SQL by exploiting improper quote-escaping in DefaultParameterFormatter.format(), which routes DELETE and CTAS statements to the _escape_hive function that backslash-escapes single quotes rather than doubling them. Because Athena and Trino do not treat backslashes as escape characters inside string literals, attacker-supplied input such as a single quote followed by SQL syntax causes the parser to terminate the string literal prematurely, enabling data exfiltration via UNION SELECT, execution of destructive statements, and attacker-controlled CTAS destination and content.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-10774

SUMMARY

Zephyr's Bluetooth Mesh subnet key management leaks one PSA Crypto key slot on every subnet-key teardown. In subsys/bluetooth/mesh/subnet.c, net_keys_create() imports the Private Beacon Key into a PSA key slot under CONFIG_BT_MESH_PRIV_BEACONS (enabled by default), but subnet_keys_destroy() guarded the matching psa_destroy_key() with CONFIG_BT_MESH_V1d1. That Kconfig symbol was removed when explicit Mesh 1.0.1 support was dropped, so the destroy branch became permanently dead code and the import is never balanced by a destroy. The imbalanced teardown is reached every time subnet keys are destroyed: deleting a subnet (Config Server NetKey Delete), completing a Key Refresh Procedure (which retires the old key set), and resetting/re-provisioning the node. The over-the-air triggers are processed only under the node's device key, so they are exercisable by the provisioner or network administrator that owns the node, reachable over the Bluetooth Mesh network. With the default CONFIG_MBEDTLS_PSA_KEY_SLOT_COUNT of 16, repeated add/delete or key-refresh cycles exhaust the shared PSA key-slot pool after roughly a dozen rounds. Once exhausted, bt_mesh_private_beacon_key() and thus subnet creation fail: the node can no longer add subnets or complete key refresh, and other PSA crypto consumers on the device may be starved, until the device is rebooted. The fix aligns the destroy guard with the import guard (CONFIG_BT_MESH_PRIV_BEACONS) so each slot is freed.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 2.4)

cvss3

Base Score: 2.4

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:H/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

0.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…